We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
+47.5%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$268M
AUM Growth
–
Cap. Flow
+$245M
Cap. Flow
% of AUM
91.48%
Top 10 Holdings %
Top 10 Hldgs %
25%
Holding
94
New
94
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
IRD
Opus Genetics
IRD
|
+$14.3M |
| 2 |
AnaptysBio
ANAB
|
+$6.34M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$5.78M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
+$5.47M |
| 5 |
Insmed
INSM
|
+$5.43M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 85.32% |
| 2 | Technology | 2.23% |
| 3 | Consumer Staples | 1.19% |
| 4 | Financials | 1.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IRD
1
Opus Genetics
IRD
$282M
| $13.4M | 5.01% |
+2,068,530
| New | +$14.3M |
|
2
Curis
CRIS
$9.41M
| $6.73M | 2.51% |
+2,055
| New | +$2.47M |
|
3
Ocular Therapeutix
OCUL
$1.85B
| $6.28M | 2.34% |
+303,174
| New | +$4.5M |
|
|
ISEE
4
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $6.24M | 2.33% |
+902,633
| New | +$5.78M |
|
5
Sutro Biopharma
STRO
$393M
| $6.01M | 2.24% |
+27,672
| New | +$4.58M |
|
|
6
Syndax Pharmaceuticals
SNDX
$1.74B
| $5.86M | 2.19% |
+263,596
| New | +$5.47M |
|
7
Genprex
GNPX
$4.05M
| $5.85M | 2.18% |
+32
| New | +$4.94M |
|
8
Verastem
VSTM
$547M
| $5.82M | 2.17% |
+227,665
| New | +$4.57M |
|
|
9
AnaptysBio
ANAB
$1.54B
| $5.62M | 2.1% |
+261,209
| New | +$6.34M |
|
|
BLU
10
DELISTED
BELLUS Health Inc.
BLU
| $5.15M | 1.92% |
+1,682,535
| New | +$4.56M |
|
11
Crinetics Pharmaceuticals
CRNX
$8.88B
| $5.11M | 1.91% |
+361,930
| New | +$5.04M |
|
|
12
Insmed
INSM
$22.6B
| $4.95M | 1.85% |
+148,743
| New | +$5.43M |
|
|
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $4.88M | 1.82% |
+153,348
| New | +$4.03M |
|
14
Cogent Biosciences
COGT
$6.95B
| $4.86M | 1.81% |
+432,563
| New | +$4.75M |
|
15
Immatics
IMTX
$1.19B
| $4.38M | 1.63% |
+405,670
| New | +$4.28M |
|
16
Nautilus Biotechnolgy
NAUT
$152M
| $4.34M | 1.62% |
+400,000
| New | +$4.21M |
|
17
Myriad Genetics
MYGN
$502M
| $4.32M | 1.61% |
+218,650
| New | +$3.53M |
|
|
EUCRU
18
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
| $4.26M | 1.59% |
+400,000
| New | +$4.06M |
|
19
Celldex Therapeutics
CLDX
$2.79B
| $4.2M | 1.57% |
+239,520
| New | +$4.31M |
|
20
Castle Biosciences
CSTL
$725M
| $4.16M | 1.55% |
+61,991
| New | +$3.36M |
|
21
Illumina
ILMN
$29.2B
| $4.14M | 1.55% |
+11,514
| New | +$3.67M |
|
22
Insulet
PODD
$11.6B
| $4.14M | 1.55% |
+16,200
| New | +$4.02M |
|
23
Aurinia Pharmaceuticals
AUPH
$1.92B
| $4.07M | 1.52% |
+293,917
| New | +$4.28M |
|
|
RCOR
24
DELISTED
Renovacor, Inc.
RCOR
| $3.97M | 1.48% |
+388,845
| New | +$3.86M |
|
|
CNST
25
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $3.87M | 1.44% |
+134,233
| New | +$3.38M |
|
Similar funds
TA
SIM
LSA
VEPM
GC
VI
BCM
VAM
Altium Capital Management's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for Altium Capital Management, which disclosed 94 positions worth $268M. Its ten largest holdings account for 25% of the portfolio.
Its largest position is Opus Genetics: 2,068,530 shares worth $13.4M.
By sector, the portfolio is most concentrated in Healthcare at 85% of assets, followed by Technology and Consumer Staples.
- Altium Capital Management's largest Q4 2020 buy was Opus Genetics: 2,068,530 shares worth $13.4M.
- Altium Capital Management's ten largest holdings make up 25% of its $268M portfolio in Q4 2020.
- Altium Capital Management disclosed 94 positions in Q4 2020, its first 13F filing on record.
Based on Altium Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.